Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending March 31, 2014

OSAKA, Japan, May 9, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", "the Company") announced today the consolidated financial results for the fiscal year ended March 31, 2013, and forecasts of consolidated results for the fiscal year ending March 31, 2014. The Company is listed on the Tokyo Stock Exchange, First Section with the stock code "4502" and prepares financial statements according to Japan GAAP.

Takeda achieved net sales growth in fiscal year 2012 (fiscal year ended March 31, 2013). This growth was supported by increases in emerging markets made possible by the acquisition of Nycomed. In addition, Takeda achieved sales gains for new products in Japan, the United States and Europe, including Nesina (treatment for type 2 diabetes), Reminyl (for patients with Alzheimer-type dementia), Azilva (for hypertension), Dexilant (for gastroesophageal reflux disease), and Uloric (for hyperuricemia for patients with chronic gout). These gains offset the decrease in sales caused by the entry of the generic version of Actos.

In addition, Takeda has been proactively making strategic investments to expand and strengthen its R&D pipeline, progressing a number of late-stage compounds and filing new drug applications in the United States, Europe and Japan. The Company has also continued the globalization of its operating model and enhanced its business infrastructure in emerging markets for future growth.

"In fiscal 2012 we chose to make critical investments to drive mid- and long-range growth while simultaneously preparing for the launch of a new Mid-Range Growth Strategy that focuses on the development of our global business operations in developed and emerging countries, and the realization of scientific and business process innovation. Our improved marketing strategy, extensive late stage pipeline and overall efforts will make Takeda's operating model robust and efficient as a world-class pharmaceutical company. Based on these initiatives, Takeda is committed to the return to a solid growth trajectory in both sales and profit as early as possible," said Yasuchika Hasegawa, President & CEO, Takeda.

For further information on the financial results as well as the company's Mid-Range Growth Strategy starting from the fiscal year 2013, please visit the Takeda web site:
Financial results: http://www.takeda.com/investor-information/results/ 
Mid-Range Growth Strategy: http://www.takeda.com/news/2013/20130509_5767.html

* The exchange rate assumptions for fiscal 2013 are 1US$=90 yen and 1 euro=120 yen.

** Special factors affecting operating income: amortization of intangible assets and goodwill resulting from corporate acquisitions, and an increase in COGS related to inventory step-up due to revaluation to fair value also resulting from corporate acquisitions.

*** Special factors affecting net income, EPS: (In addition to the factors affecting operating income) non-operating expenses related to corporate acquisitions, refund relating to transfer pricing

**** EBITDA excl. extraordinary income and loss is calculated by adding the following to ordinary income: amortization of intangible assets, amortization of goodwill, and non-operating expenses resulting from corporate acquisitions etc., depreciation and interest expenses.

Forward-looking statements:

This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. 

All forward-looking statements are based on judgments derived from the information available to the Company at this time.  Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.

SOURCE Takeda Pharmaceutical Company Limited